Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84.2M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
7.17M
-
Shares change
-
+189K
-
Total reported value, excl. options
-
$33.6M
-
Value change
-
+$912K
-
Number of buys
-
7
-
Number of sells
-
-1
-
Price
-
$4.68
Significant Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q2 2020
19 filings reported holding VRNA - Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share as of Q2 2020.
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.17M shares
of 84.2M outstanding shares and own 8.52% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (1.49M shares), ORBIMED ADVISORS LLC (1.25M shares), NEA Management Company, LLC (1.22M shares), Abingworth LLP (902K shares), NOVO Holdings A/S (741K shares), venBio Partners LLC (457K shares), Aisling Capital Management LP (444K shares), Tekla Capital Management LLC (253K shares), D.A. DAVIDSON & CO. (117K shares), and WEDBUSH SECURITIES INC (109K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.